Small Cap Feast
Small Cap Feast – 21 May 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
Jewel UK Midco Limited, the parent company of The Watches of Switzerland Group Limited, is looking to join the premium segment of the main market. Offer TBC, expect TBC
Main Market (Standard)
IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019
Pure Gold— TSX listed seeking a London listing. Focused on Madsen Red Lake Gold Deposit. Feasibility Study outlines a robust 12-year, high grade, 800 tonne per day underground mining operation with low initial capital cost of C$95mm and strong financial performance with an after-tax NPV of C$247mm . Introduction only at this point Mkt cap CA£138m.
Main Market (Specialist Funds)
Riverstone Credit Opportunities Income – raising US$200m—will seek to generate consistent shareholder returns predominantly in the form of income distributions principally by making senior secured loans to energy-related businesses. Due 24 May
Essensys plc—a provider of mission-critical SaaS platforms and on-demand cloud services to the high growth flexible workspace industry, plans to join AIM. £28m raised. Half primary, half shareholder sell down expected 29 May 2019. Mkt cap £72.6m. Issue price 151p.
Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019.
SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m
Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.
Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019
SSuINOx—has developed a hydrocarbon fuels conditioning and emulsifying process that enables more efficient fuel combustion, leading potentially to reduced fuel usage and significantly lowered emissions. Offer TBA.
The Vitec Group (VTC.L) 1153p £525m
AGM Statement from the international provider of premium branded products and solutions to the fast moving and growing “image capture and content creation” market. The Group’s trading for the four months ended 30 April 2019 was in line with expectations:. The Board’s expectations for achieving progress in 2019 are unchanged.
The Group announces a significant investment in its web marketing and e-tail capabilities in its Imaging Solutions Division, specifically to recruit a global team to transform its digital competencies, and to reorganise the sales and marketing network by distribution channel. The total investment is expected to be c. €8.5m. Savings are expected to build over time to an annual run rate of c. €3.0m by the end of 2021.
Proton Partners (NEX:PPI) 245p £360m
The group committed to providing innovative cancer care of the highest quality, has today announced the commencement of high energy proton beam therapy services at the Rutherford Cancer Centre North East in Bomarsund, Northumberland.
The first prospective cohort of patients at the Rutherford Cancer Centre North East are already undergoing assessment for proton beam therapy.
The Group’s oncology centres in the UK offer a comprehensive range of cancer treatments to patients including high energy proton beam therapy, radiotherapy, chemotherapy, imaging and ancillary wellbeing services.
High energy proton beam therapy is a type of radiotherapy used in cancer treatment, delivering heavily charged protons in a more targeted manner to reduce damage to peripheral tissue and organs. It can also help reduce unwelcome side effects.
Epwin Group (EPWN.L) 81p £115m
AGM statement from the manufacturer of low maintenance building products, supplying the Repair, Maintenance and Improvement (“RMI”), new build and social housing sectors. “The Group has continued its encouraging start to the year, consistent with meeting market expectations for 2019. Trading has been pleasing, particularly in the Window Systems business which has continued to win new customers.
The Amicus distribution and PVS decking acquisitions are integrating well and performing in line with our expectations. The Group is also pleased to launch its aluminium window system today, in line with the project plan, and has continued to progress the building of its new warehouse and finishing plant in Telford which will be operational in early 2020.
The Board retains its positive view of the medium-term prospect for the market given the continued under investment in RMI, strong new build demand and nascent demand in social housing markets. We look forward to updating shareholders further
APC Technology (APC.L) 9.5p £18m
HY Fed 19 results from the provider of design-in, specification and distribution services for specialist electronic components and systems, lighting technologies and connectivity products.
Revenue increased to £10.6m (H1 2018: £8.6m), up 24% from the £8.5m posted in H2 2018.
Adjusted profit before tax increased by 71% to £0.66m (H1 2018: £0.38m) with adjusted earnings per share increasing by 31% compared with H1 2018.
Net debt decreased further by £1.3m to £2.7m (H1 2018: £4.0m) with all high interest-bearing loan notes now repaid.
“The Group continues to reap the benefits of its clear strategy for moving forward with profitable cash-generative growth. This strategy has three tactical strands: “
• Increase revenue through APC’s established and growth technologies.
• Growth by signing new proven technology partners.
• Sales growth through bolt-on acquisitions.
Mortgage Advice Bureau (MAB1.L) 570p £296m
“Adviser numbers have continued to grow since our final results statement on 19 March 2019 and increased to 1,272 advisers as at 17 May 2019, representing an increase of 5% year to date. We continue to have good visibility that supports our anticipated growth in Adviser numbers from new Appointed Representatives (“ARs”). Although some of our existing ARs with direct links to the estate agency sector continue to pause their expansion plans and delay filling vacancies as a result of reduced confidence amid political uncertainty resulting in a somewhat subdued housing market, the majority of our ARs continue to hold strong growth plans for 2019 and 2020. However, against the backdrop of continuing uncertainty we have seen housing transactions taking longer to complete in this financial year to date, impacting the timing of our banked revenue.” “We believe MAB is ideally positioned to continue increasing its market share, and to focus on wider Group success and profitability through new opportunities and broadening our addressable market.”
Amryt Pharma (AMYT.L) 12.25p £34m suspended
· Amryt has agreed to acquire Aegerion in an all-paper transaction
· The combined group had 2018 pro-forma combined revenues of $136.5m
· Pre-money implied transaction equity valuations: Amryt $120m and Aegerion $190.7m
Contingent Value Rights (“CVRs”) will be issued to Amryt stakeholders that could result in the payment of up to $85m (settled in cash or stock) based on certain AP101 milestones being achieved.
Creates a rare disease business with two approved products – lomitapide (Lojuxta® / Juxtapid®) and metreleptin (Myalept® / Myalepta®)
Amryt plans to raise $60m in equity concurrent with closing of the Transaction and certain Aegerion bondholders have agreed to backstop this equity raise .
Amryt will continue to be listed on the London Stock Exchange’s Alternative Investment Market, Euronext Growth Market in Dublin and after the Transaction will pursue a dual-listing on NASDAQ.
IMImobile (IMO.L) 312p £208m
“The global cloud communications software and solutions provider, has signed a partnership agreement with Telia Norway, with an option to extend to the wider Telia Company – the leading telecom operator in the Nordic/Baltics. The partnership agreement will enable Telia to resell IMImobile’s cloud products, including its enterprise cPaaS (Communications Platform as a Service) offering, IMIconnect, to its enterprise customers. IMIconnect enables businesses to rapidly launch and orchestrate two-way, trigger-based customer communications, across 10+ channels.
Driven by the changes in person to person communications, consumers now expect interactions with businesses to be personalised, relevant, contextual, interactive and conducted in real time. IMImobile is helping Telia to keep pace with changing consumer expectations and offer innovative communications solutions for their enterprise customers. Telia will also be looking into using IMIconnect itself in order to create interactive customer journeys.
Renalytix (RENX.L) 202p £109m
The developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio of advanced diagnostic and prognostic solutions in kidney transplant.
As previously announced, RenalytixAI formed the FractalDx investigator group as part of its commercial programme for advanced diagnostic tests expected to make significant improvements in the identification and monitoring for kidney transplant rejection, and to aid in accurate dosing of immune-suppression therapy.
“Predicting transplant rejection before damage to the transplanted kidney occurs remains a major unmet need. Accurately determining rejection risk for each transplant recipient allows individualised treatment to be initiated before the transplanted kidney is attacked and damaged by the immune system leading to improved patient care and successful outcomes.”
Dods Group (DODS.L) 7.5p £25m
The “business intelligence company, announces that Munira Ibrahim has been appointed as Chief Revenue Officer with immediate effect.
Munira has spent the past five years as Senior Vice President of Sales and Content Solutions at Thomson Reuters, following her position as Director of Global Sales Operation at CNBC, part of NBC Universal.
Prior to this, Munrina was Financial Controller at Polygram, having gained a degree in Banking and International Finance from City University.”
Simon Presswell, CEO of Dods Group Plc, said, “The addition of Munira to the management team is further evidence of the scale of our ambition at Dods to create the world’s leading augmented intelligence business.”
Boku (BOKU.L) 130p £316m
The “independent carrier commerce and identity verification company, is pleased to announce a global expansion of Boku Identity, extending its identity verification capabilities to over 60 countries by the end of 2019. Boku Identity is trusted by leading Fortune 500 companies, including PayPal and Western Union, and has already performed over one billion user authentications across North America, Western Europe, and Asia.
Boku Identity is powered by the Boku Platform, which aggregates and harmonizes mobile network operator systems across 58 countries worldwide. By combining the Boku Platform with the identity verification and authentication capabilities from recently acquired Danal Inc., Boku Identity helps global enterprises across multiple industries effectively reduce identity fraud, drive conversions, ensure compliance, and deliver a superior customer experience.”
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.